Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 -2.93%84 PEG Ratio is 2.49 as of Jul. 24, 2026, which is 33% below its 10-year median of 3.72. GuruFocus rates SHSE:688315 with a GF Score™ of 84/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 94 Biotechnology companies, Novogene Co ranks worse than 62.77% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Novogene Co's PE Ratio without NRI is 25.68. Novogene Co's 5-Year EBITDA growth rate is 10.30%. Therefore, Novogene Co's PEG Ratio for today is 2.49.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Novogene Co's PEG Ratio or its related term are showing as below:
SHSE:688315'
s PEG Ratio Range Over the Past 10 Years
Min: 2.49 Med: 3.72 Max: 9.08
Current: 2.49
During the past 11 years, Novogene Co's highest PEG Ratio was 9.08. The lowest was 2.49. And the median was 3.72.
SHSE:688315's PEG Ratio is ranked worse than 62.77% of 94
companies
in the Biotechnology industry
Industry Median: 1.85
vs SHSE:688315: 2.49
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Novogene Co (SHSE:688315) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Novogene Co PEG Ratio Related Terms
Novogene Co PEG Ratio Historical Data
* Premium members only.
The historical data trend for Novogene Co's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Novogene Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Novogene Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Novogene Co (SHSE:688315) has a PEG Ratio of 2.49 as of Jul. 24, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Novogene Co and its competitors. This is 33% below median its historical median of 3.72. Over the past decade, Novogene Co's PEG Ratio has ranged from 2.49 to 9.08. According to the industry distribution chart, Novogene Co ranks #59 out of 94 companies in the Biotechnology industry, placing it in the top 62.8%.
Is Novogene Co's PEG Ratio too high?
Novogene Co's current PEG Ratio of 2.49 is 33% below median its 10-year median of 3.72. Over the past 10 years, this metric has ranged from a low of 2.49 to a high of 9.08. The Biotechnology industry median PEG Ratio is 1.85. Novogene Co's value of 2.49 is 34.6% above this industry median. Based on the distribution chart, Novogene Co ranks #59 out of 94 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Novogene Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #59 out of 94 companies for PEG Ratio. This places Novogene Co in the lower half of its industry. The industry median PEG Ratio is 1.85. Novogene Co's value of 2.49 is 34.6% above this benchmark. Historically, Novogene Co's own PEG Ratio has ranged from 2.49 to 9.08 over the past decade. While the company's 10-year median is 3.72 vs. the industry median of 1.85, Novogene Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.85, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novogene Co's current PEG Ratio of 2.49 is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Novogene Co and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novogene Co's current PEG Ratio is 2.49, which is 33% below median its own 10-year median of 3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥11.94 — trading 25.3% below its estimated fair value. The current PEG Ratio is 2.49, which is 33% below median its 10-year median of 3.72 and 34.6% above the Biotechnology industry median of 1.85. Novogene Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current PEG Ratio is 2.49 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥11.94 is trading 25.3% below its estimated GF Value™ of ¥15.99.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
PEG Ratio: 2.49 (33% below median its 10-year median of 3.72)
GF Value™: ¥15.99 vs. price of ¥11.94 (25.3% below fair value)
Industry Position: 34.6% above the Biotechnology median (#59 of 94)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
84GF Score
Get the complete analysis for SHSE:688315
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
